High Resolution Mass Spectrometry (HR-MS)

Offering experience with state-of-the-art HR-MS technology.

Building on 50+ years of experience providing bioanalytical services, and 20+ years working to GLP and GCP, Resolian continues to invest in the latest High Resolution Mass Spectrometry (HR-MS) technology. 

Reach out to us directly to learn more about Resolian’s High Resolution Mass Spectrometry services.

High Resolution Mass Spectrometry – Why Is It Beneficial?

  • Reduced background noise and interference can allow lower detection limits to be achieved and generation of more robust data
  • With a more selective mass-based detection, sample preparation techniques can be simplified, leading to faster method development and more robust assays
  • Acquisition of full scan data enables faster MS optimization and the ability to interrogate data post-run for enhanced troubleshooting ability
  • High resolution allows for the intact analysis of proteins, informing on their in vivo catabolitic fate

Integrated Support from Early Discovery to Late-Phase Clinical Trials

Beyond specialist HR-MS experience, Resolian’s dedicated LC-MS team offers integrated support from early discovery to late-phase clinical trials, advising you on the regulations applicable to your project.

Resolian’s integrated services include:
  • Fast method development for discovery compounds
  • Method development and validation for GLP TK studies and GCP clinical trials
  • Fast turnaround for phase I clinical studies
  • Pharmacokinetic data analysis using validated software systems (e.g., WinNonlin)
  • Logistical support for clinical sample management including sample collection kit production and supply of sampling kits, labels, investigator manual and shipping
  • Data management using LIMS or specialist software

Our
Resources

Our Resources

Biomarker Assay List

Bioanalytical LC-MS/MS Assay List 

Immunoassay Pharmacokinetics

Scroll to Top

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

Patrick Bennett

Chief Executive Officer

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now CEO at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.